Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2008;102:1512-1519
Published online before print May 22, 2008, doi: 10.1161/CIRCRESAHA.108.172064
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
102/12/1512    most recent
CIRCRESAHA.108.172064v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, K.
Right arrow Articles by Silverstein, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, K.
Right arrow Articles by Silverstein, R. L.
Related Collections
Right arrow Cell signalling/signal transduction
Right arrow Arterial thrombosis
Right arrow Platelets
(Circulation Research. 2008;102:1512.)
© 2008 American Heart Association, Inc.


Molecular Medicine

A Specific CD36-Dependent Signaling Pathway Is Required for Platelet Activation by Oxidized Low-Density Lipoprotein

Kan Chen, Maria Febbraio, Wei Li, Roy L. Silverstein

From the Program in Cell Biology (K.C., M.F., R.L.S.), Case Western Reserve University; and Department of Cell Biology (M.F., W.L., R.L.S.), Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio.

Correspondence to Roy L. Silverstein, MD, Department of Cell Biology NC10, Lerner Research Institute, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195. E-mail silverr2{at}ccf.org

Platelet hyperactivity associated with hyperlipidemia may contribute to development of a prothrombotic state. We previously showed that oxidized low-density lipoprotein (oxLDL) formed in the setting of hyperlipidemia and atherosclerosis activated platelets in a CD36-dependent manner. We now show that mitogen-activated protein kinase c-Jun N-terminal kinase (JNK)2 and its upstream activator MKK4 were phosphorylated in platelets exposed to oxLDL. Using apoE–/– mice as a model of hyperlipidemia, we showed that JNK was constitutively phosphorylated in platelets in a CD36-dependent manner. Inhibition of src kinase activity reduced JNK phosphorylation by oxLDL. Immunoprecipitations revealed that active phosphorylated forms of src kinases Fyn and Lyn were recruited to CD36 in platelets exposed to oxLDL. Pharmacological inhibition of the mitogen-activated protein kinase JNK or src family kinases abolished platelet activation by oxLDL in vitro. Using a murine carotid artery thrombosis model we demonstrated CD36-dependent phosphorylation of platelet JNK within thrombi. Furthermore, pharmacological inhibition of JNK prolonged thrombosis times in wild-type but not cd36-null mice in vivo. These findings suggest that a specific CD36-dependent signaling pathway is required for platelet activation by oxLDL and may provide insights related to development of novel antiplatelet therapies more relevant to atherothrombosis than to normal hemostasis.


Key Words: CD36 • JNK • thrombosis • hyperlipidemia




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
D. J. Kennedy, S. D. Kuchibhotla, E. Guy, Y. M. Park, G. Nimako, D. Vanegas, R. E. Morton, and M. Febbraio
Dietary Cholesterol Plays a Role in CD36-Mediated Atherogenesis in LDLR-Knockout Mice
Arterioscler Thromb Vasc Biol, October 1, 2009; 29(10): 1481 - 1487.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
H. Sun, A. Swaim, J. E. Herrera, D. Becker, L. Becker, K. Srivastava, L. E. Thompson, M. R. Shero, A. Perez-Tamayo, B. Suktitipat, et al.
Platelet Kainate Receptor Signaling Promotes Thrombosis by Stimulating Cyclooxygenase Activation
Circ. Res., September 11, 2009; 105(6): 595 - 603.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. Harb, K. Bujold, M. Febbraio, M. G. Sirois, H. Ong, and S. Marleau
The role of the scavenger receptor CD36 in regulating mononuclear phagocyte trafficking to atherosclerotic lesions and vascular inflammation
Cardiovasc Res, July 1, 2009; 83(1): 42 - 51.
[Abstract] [Full Text] [PDF]


Home page
Sci SignalHome page
R. L. Silverstein and M. Febbraio
CD36, a Scavenger Receptor Involved in Immunity, Metabolism, Angiogenesis, and Behavior
Sci. Signal., May 26, 2009; 2(72): re3 - re3.
[Abstract] [Full Text] [PDF]


Home page
Cleveland Clinic Journal of MedicineHome page
R. L. SILVERSTEIN
Inflammation, atherosclerosis, and arterial thrombosis: Role of the scavenger receptor CD36
Cleveland Clinic Journal of Medicine, April 1, 2009; 76(Suppl_2): S27 - S30.
[Abstract] [Full Text] [PDF]